Human leukocyte antigen antibodies and chronic rejection: From association to causation

Transplantation

Volumn 86, Issue 3, 2008, Pages 377-383

  Terasaki, Paul I ^a   Cai, Junchao ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Chronic rejection; HLA antibody; Kidney transplant

Indexed keywords

HLA ANTIBODY; ALLOANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; CHRONIC GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; PRIORITY JOURNAL; REVIEW; BLOOD; CHRONIC DISEASE; DOSE RESPONSE; DRUG EFFECT; EDITORIAL; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; ORGAN TRANSPLANTATION; PLASMAPHERESIS; RISK FACTOR; TIME;

ANTIBODY SPECIFICITY; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EVIDENCE-BASED MEDICINE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; ORGAN TRANSPLANTATION; PLASMAPHERESIS; RISK FACTORS; TIME FACTORS;

EID: 50549089591     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31817c4cb8     Document Type: Review

References (97)

1. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319.
2. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
3. Terasaki PI, Cai J. Humoral theory of transplantation: Further evidence. Curr Opin Immunol 2005; 17: 541.
4. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. BMJ 1950; 4682: 739.
5. Doll R, Hill AB. The mortality of doctors in relation to smoking habits; a preliminary report. BMJ 1954; 4877: 1451.
6. Hill AB. The environment and disease: Association orcausation? Proc R Soc Med 1965; 58: 295.
7. Morris PJ, Williams GM, Hume DM, et al. Serotyping for homotransplantation. XII. Occurrence of cytotoxic antibodies following kidney transplantation in man. Transplantation 1968; 6: 392.
8. Morris PJ, Mickey MR, Singal DP, etal. Serotyping for homotransplantation. XXII. Specificity of cytotoxic antibodies developing after renal transplantation. BMJ 1969; 1: 758.
9. Jeannet M, Pinn VW, Flax MH, et al. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111.
10. Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1289.
11. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532.
12. Mizutani K, Terasaki P, Bignon JD, et al. Association of kidney transplant failure and antibodies against MICA. Hum Immunol 2006; 67: 683.
13. PalomarR,Lopez-HoyosM,Pastor JM,etal. ImpactofHLA antibodies on transplant glomerulopathy. Transplant Proc 2005; 37: 3830.
14. Panigrahi A, Deka R, Bhowmik D, et al. Functional assessment of immune markers of graft rejection: A comprehensive study in live-related donor renal transplantation. Clin Transplant 2006; 20: 85.
15. Panigrahi A, Gupta N, Siddiqui JA, et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 2007; 68: 362.
16. Sun Q, Liu Z, Yin G, et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: A report of three cases. Transplantation 2005; 79: 1759.
17. Vasilescu ER,Ho EK, Colovai AI, et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 2006; 67: 597.
18. Zhang Q, Liang LW, Gjertson DW, et al. Development of posttrans-plant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 2005; 79: 591.
19. Opelz G. Non-HLA transplantation immunity revealed by lymphocy-totoxic antibodies. Lancet 2005; 365: 1570.
20. Collins AB, Chicano SL, Cornell LD, et al. Putative antibody-mediated rejection with C4d deposition in HLA-identical, ABO-compatible renal allografts. Transplant Proc 2006; 38: 3427.
21. Cai J, Terasaki PI, Bloom DD, et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919.
22. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implicationsof developmentofdonor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
23. Tambur AR, Buckingham M, McDonald L, et al. Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: The role of epitope sharing and epitope matching. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 399.
24. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019.
25. McKay M, Pinney S, Gorwara S, et al. Anti-human leukocyte antigen antibodies are associated with restenosis after percutaneous coronary intervention for cardiac allograft vasculopathy. Transplantation 2005; 79: 1581.
26. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131.
27. Masson E, Stern M, Chabod J, et al. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26: 642.
28. Ionescu DN, Girnita AL, ZeeviA,etal. C4d depositioninlung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005; 15: 63.
29. Muro M, Marin L, Miras M, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: Experience of one centre. Transpl Immunol 2005; 14: 91.
30. Kato T, Mizutani K, Terasaki P, et al. Association of emergence of HLA antibody and acute rejection in intestinal transplant recipients: A possible evidence of acute humoral sensitization.Transplant Proc 2006; 38: 1735.
31. Melcher ML, Olson JL, Baxter-Lowe LA, et al. Antibody-mediated rejection of a pancreas allograft. Am J Transplant 2006; 6: 423.
32. Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation 2006; 82: 180.
33. Mizutani K, Terasaki PI, Shih RN, et al. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody. Hum Immunol 2006; 67: 223.
34. Suarez-Alvarez B, Lopez-Vazquez A, Diaz-Pena R, et al. Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome. Transpl Immunol 2006; 17: 43.
35. Suarez-Alvarez B, Lopez-Vazquez A, Gonzalez MZ, et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007; 7: 1842.
36. ZouY, Heinemann FM, Grosse-Wilde H, etal. Detectionof anti-MICA antibodiesinpatients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 2006; 67: 230.
37. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
38. El-Awar N, Terasaki PI, Lazda V, et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti HLA antibodies. Transplant Proc 2002; 34: 2531.
39. MizutaniK,TerasakiP,Rosen A,etal. Serial ten-year follow-upofHLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
40. Mizutani K, Shibata L, Ozawa M, et al. Detection of HLA and MICA antibodies before kidney graft failure. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 255.
41. Kinukawa T, Kato M, Terasaki P, et al. Retrospective antibody analysis of thirty patients with kidney graft failure. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 291.
42. Ozawa M, Rebellato L, Terasaki P, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 265.
43. Van den Berg-Loonen E, Terasaki P, Kohanof S, et al. Longitudinal testing of seventy-six renal allograft patients of HLA antibodies: Maastricht experience. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 305.
44. Supon P, Constantino D, Hao P, et al. Prevalence of donor-specific anti-HLA antibodies during episodes ofrenal allograft rejection. Transplantation 2001; 71: 577.
45. Gibney EM, Cagle LR, Freed B, et al. Detection of donor-specific antibodies using HLA-coated microspheres: Another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21: 2625.
46. Lenaers JI, Christiaans MH, Voorter CE, et al. Relevance of posttrans-plant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. Transplantation 2006; 82: 1142.
47. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
48. El-Awar N, Lee JH, Tarsitani C, et al. HLA class I epitopes: Recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 2007; 68: 170.
49. Duquesnoy RJ, Askar M. HLAMatchmaker: A molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP. Hum Immunol 2007; 68: 12.
50. El-Awar N, Akaza T, Terasaki PI, et al. Human leukocyte antigen class I epitopes: Update to 103 total epitopes, including the C locus. Transplantation 2007; 84: 532.
51. Cai J, Kohanof S, Terasaki PI. HLA-DR antibody epitopes. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 103.
52. Deng CT, CaiJ, TarsitaniC,etal. HLA class IIDQepitopes. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 115.
53. Piazza A, Poggi E, Ozzella G, et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: Alloantibody characterization by flow cytometric techniques. Transplantation 2006; 81: 1298.
54. Adeyi OA, Girnita AL, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14: 53.
55. Mao Q, Terasaki PI, Cai J, et al. Analysis of HLA class I specific antibodies in patients with failed allografts. Transplantation 2007; 83: 54.
56. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failureof kidney grafts ina five-year longitudinal study. Am J Transplant 2007; 7: 864.
57. Cai J, Terasaki PI, Mao Q, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DRantigens.AmJTransplant2006; 6: 2947.
58. Qiu J, Cai J, Terasaki PI, et al. Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005; 80: 1511.
59. Terasaki P, Ozawa M, Castro R. Four-year follow-up of a prospective trial ofHLA and MICA antibodies on kidney graft survival.AmJ Transplant 2007; 7: 408.
60. Worthington JE, McEwen A, McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007; 83: 398.
61. Kamimaki I, Ishikura K, Hataya H, et al. A case of allograft dysfunction with antibody-mediated rejection developing 13 yr after kidney transplantation. Clin Transplant 2007; 21(suppl 18): 60.
62. Weinstein D, Braun WE, Cook D, et al. Ultra-late antibody-mediated rejection 30 years after a living-related renal allograft. Am J Transplant 2005; 5: 2576.
63. Shimizu A, Yamada K, Sachs DH, et al. Persistent rejection of peritu-bular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int 2002; 61: 1867.
64. Jin YP, Jindra PT, Gong KW, et al. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005; 79(3 suppl): S19.
65. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743.
66. Miura M, Ogawa Y, Kubota KC, et al. Donor-specific antibody in chronic rejectionisassociated with glomerulopathy, thickeningofperi-tubular capillary basement membrane, but not C4d deposition. Clin Transplant 2007; 21(suppl 18): 8.
67. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: Sub-clinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124.
68. Mengel M, Bogers J, Bosmans JL, et al. Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 2005; 5: 1050.
69. Mizutani K, Terasaki P, Hamdani E, et al. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007; 7: 1027.
70. Jutte NH, Knoop CJ, Heijse P, et al. Cytotoxicity of graft-derived lymphocytes: Specific for donor heart endothelial cells? J Heart Lung Transplant 1997; 16: 209.
71. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051.
72. Alkhatib B, Freguin-Bouilland C, Litzler PY, et al. Antidonor humoral transfer induces transplant arteriosclerosis in aortic and cardiac graft models in rats. J Thorac Cardiovasc Surg 2007; 133: 791.
73. Russell PS, Chase CM, Winn HJ, et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135.
74. Stetson CA Jr, Demopoulos R. Reactions of skin homografts with specific immune sera. Ann N Y Acad Sci 1958; 73: 687.
75. Campos EF, Tedesco-Silva H, Machado PG, et al. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006; 6: 2316.
76. Gerbase-DeLima M, Campos EF, Tedesco-Silva H, et al. Anti-HLA class II antibodies and chronic allograft nephropathy. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 201.
77. Langan LL, D'orsogna L, Park LP, et al. HLA antibodies and soluble CD30 are associated with poor renal graft outcome: Updated results of a single-center cross-sectional study. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 219.
78. Lachmann N, Terasaki P, Schonemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: A prospective trial with a four-year follow-up. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 171.
79. Piazza A, Poggi E, Ozzella G, et al. Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: Results of sixteen-year monitoring by flow cytometry. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 323.
80. Morales-Buenrostro L, Castro R, Terasaki PI. Impact of immunosup-pression on HLA-antibodies formation. In: Terasaki P, ed. Clinical transplants 2006. Los Angeles, Terasaki Foundation Lab 2007, p 227.
81. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 2005; 79: 466.
82. Zachary AA, Montgomery RA, Leffell MS. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.Hum Immunol 2005; 66: 364.
83. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasma-pheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346.
84. Jordan S. IVIG vs. plasmapheresis for desensitization: Which is better? Am J Transplant 2006; 6: 1510.
85. HansenR,SeifeldinR,Noe L. Medication adherence inchronic disease: Issues in posttransplant immunosuppression. Transplant Proc 2007; 39: 1287.
86. Terasaki PI, Marchioro TL, Starzl TE. Sero-typing of human lymphocyte antigens: Preliminary trials on long term kidney homograft survivors. Washington, DC, National Academy of Science, 1965.
87. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
88. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662.
89. Williams GM, Hume DM, Hudson RP Jr, et al. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279: 611.
90. Terasaki PI, Kreisler M, Mickey RM. Presensitization and kidney transplant failures. Postgrad Med J 1971; 47: 89.
91. Zou Y, Stastny P, Susal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293.
92. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3: 1488.
93. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307.
94. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
95. Cook DJ, Terasaki PI, Iwaki Y, et al. The flow cytometry crossmatch in kidney transplantation. Clin Transpl 1987: 409.
96. Ogura K, Terasaki PI, Johnson C, et al. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation. Transplantation 1993; 56: 294.
97. Yen E,Hardinger K, Brennan DC, et al. Cost-effectiveness of extending medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004; 4: 1703.